You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

ARMONAIR RESPICLICK Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Armonair Respiclick patents expire, and when can generic versions of Armonair Respiclick launch?

Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. There are twelve patents protecting this drug.

This drug has two hundred and seventy-nine patent family members in thirty-one countries.

The generic ingredient in ARMONAIR RESPICLICK is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Armonair Respiclick

A generic version of ARMONAIR RESPICLICK was approved as fluticasone propionate by FOUGERA PHARMS on May 14th, 2004.

  Try a Trial

US Patents and Regulatory Information for ARMONAIR RESPICLICK

ARMONAIR RESPICLICK is protected by twelve US patents and three FDA Regulatory Exclusivities.

Patents protecting ARMONAIR RESPICLICK

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Dry powder inhalation apparatus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Dry powder inhalation apparatus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Dry powder inhalation apparatus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Process for preparing a medicament
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Dose counter for inhaler having a bore and shaft arrangement
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting ARMONAIR RESPICLICK

NEW STRENGTH
Exclusivity Expiration: ⤷  Try a Trial

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Try a Trial

NEW PATIENT POPULATION
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-003 Jan 27, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-002 Jan 27, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-003 Jan 27, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-003 Jan 27, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-003 Jan 27, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-001 Jan 27, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ARMONAIR RESPICLICK

International Patents for ARMONAIR RESPICLICK

See the table below for patents covering ARMONAIR RESPICLICK around the world.

Country Patent Number Title Estimated Expiration
United Kingdom 2366208 Dose counter for medicament inhaler ⤷  Try a Trial
European Patent Office 4169040 SYSTÈME D'INHALATEURS (INHALER SYSTEM) ⤷  Try a Trial
European Patent Office 2987523 COMPTEURS DE DOSES POUR INHALATEURS (DOSE COUNTERS FOR INHALERS) ⤷  Try a Trial
Israel 276280 יחידת פיקוח על ציות עבור משאף מופעל-נשימה (Compliance monitoring module for an inhaler) ⤷  Try a Trial
Canada 2586482 MAGASIN A DOSE D'ADMINISTRATION PRE-CALIBREE POUR INHALATEURA POUDRE SECHE ACTIONNE PAR LA RESPIRATION (PRE-METERED DOSE MAGAZINE FOR BREATH-ACTUATED DRY POWDER INHALER) ⤷  Try a Trial
China 114306839 呼吸驱动吸入器的依从性监控模块 (Compliance monitoring module for breath-driven inhaler) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ARMONAIR RESPICLICK

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2506844 2018C/022 Belgium ⤷  Try a Trial PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1519731 92269 Luxembourg ⤷  Try a Trial PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
1305329 SPC/GB08/026 United Kingdom ⤷  Try a Trial PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
2506844 LUC00077 Luxembourg ⤷  Try a Trial PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1519731 132013902182575 Italy ⤷  Try a Trial PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
2506844 1890025-8 Sweden ⤷  Try a Trial PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.